Stock Screener App

Frei -

Installieren

84.47

1.19% -0.645

Arrowhead Pharmaceuticals Inc (ARWR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARWR? Forum Prognose Aktiensplit

Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten

ARWR Looks 63.8% Overvalued on GF Value™ - GuruFocus

ARWR Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus

ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - Yahoo Finance

Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - Yahoo Finance

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe HypertriglyceridemiaSlideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha

ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus

Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says - marketscreener.com

Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Yahoo Finance

Stifel reiterates Buy rating on Arrowhead Pharma stock at $104 - Investing.com

Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split - BioSpace

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Investing News Network

Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies (ARWR:NASDAQ) - Seeking Alpha

Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - finance.yahoo.com

Have Arrowhead Pharmaceuticals Insiders Been Selling Stock? - simplywall.st

Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals - Moomoo

Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com

Arrowhead Pharmaceuticals (ARWR) Director Adeoye Olukotun Sells 2,000 Shares - GuruFocus

Arrowhead (ARWR) Stock: Slides 3.28% to $86.47 in the Latest Reading; Technical Setup: the $82.15 to $90.79 Range Remains in Focus at the CloseHigh Dividend Factor - Vinanet

Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR - TradingView

Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares - Stock Titan

Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares - Stock Titan

ARWR Looks 53.4% Overvalued on GF Value™ - GuruFocus

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides - Arrowhead Pharmaceuticals, Inc.

ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView

Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion - TipRanks

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan

Arrowhead Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | HDP1 | US04280A1007 - marketscreener.com

Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - Sahm

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis: A Biotech Gem with 24.74% Upside - DirectorsTalk Interviews

Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st

FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat

Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat

Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com

Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo

Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Yahoo Finance

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - marketbeat.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results - MarketBeat

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Arrowhead Pharmaceuticals Inc.R (HDP1.DU) Q3 FY2026 earnings call transcript - Yahoo Finance

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Arrowhead Pharmaceuticals, Inc.

The Manufacturers Life Insurance Company Has $10.06 Million Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Dimensional Fund Advisors LP - MarketBeat

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)August 3, 2026 - BioSpace

Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh - TradingView

Janus Henderson Group PLC Acquires 156,544 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake - Stock Titan

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones - Yahoo Finance

RPRX

$60.13

0.71%

INSM

$129.12

2.84%

ROIV

$41.64

0.61%

ALNY

$255.32

1.75%

ONC

$348.96

0.72%

RVMD

$209.70

1.11%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters